

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

---

THE GENERAL HOSPITAL  
CORPORATION and  
DANA-FARBER CANCER  
INSTITUTE, INC.,

Plaintiffs,

v.

ESOTERIX GENETIC  
LABORATORIES, LLC and  
LABORATORY CORPORATION  
OF AMERICA,

Defendants.

---

C.A. No. 1:18-cv-11360-IT

**NOTICE OF MOOTNESS OF DEFENDANTS' MOTION TO DISMISS**

Plaintiffs The General Hospital Corporation and Dana-Farber Cancer Institute, Inc. (together, the "plaintiffs") hereby give notice that, in light of the plaintiffs timely filing of an Amended Complaint (Dkt. No. 18) pursuant to Federal Rule of Civil Procedure 15(a), the motion of defendants Esoterix Genetic Laboratories, LLC and Laboratory Corporation of America Holdings (a/k/a Laboratory Corporation of America) to dismiss (Dkt. No. 9) is moot, and should therefore be denied.

Respectfully submitted,

THE GENERAL HOSPITAL  
CORPORATION AND DANA-FARBER  
CANCER INSTITUTE, INC.

By their attorneys,

/s/ Carolyn A. Marcotte

Douglas J. Nash (BBO# 633050)  
Carolyn A. Marcotte (BBO# 663616)  
Barclay Damon LLP  
One Financial Center, Suite 1701  
Boston, MA 02111  
(617) 274-2900  
dnash@barclaydamon.com  
cmarcotte@barclaydamon.com

Dated: July 18, 2018

**CERTIFICATE OF SERVICE**

I, Carolyn A. Marcotte, certify that on July 18, 2018, this Notice filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing and paper copies will be sent to the non-registered participants.

/s/ Carolyn A. Marcotte

Carolyn A. Marcotte